Please assess the completion status of the following clinical trial:

Trial Title: The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients age ≥ 18 years old admitted to San Francisco General Hospital for injury with at least one risk factor for venous thromboembolism (VTE).~Risk factors are: Age ≥ 40 years, pelvic fracture, lower extremity fracture, spinal cord injury, shock or head injury, major operative procedure, mechanical ventilation \> 3 days, venous injury~Exclusion Criteria:~* prisoners~* pregnant patients~* patients who are anticipated to have a \< 5 day length of stay as determined by the admitting trauma surgeon~* patients who decline to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1A (Type: EXPERIMENTAL): Patients at high risk for venous thromboembolism (criteria: age\>=40, pelvic fracture, lower extremity fracture, shock on presentation, spinal cord injury, head injury with Abbreviated Injury Scale (AIS) \>=3). These patients will receive fondaparinux 2.5mg via subcutaneous administration (SubQ) daily.
- 1B (Type: ACTIVE_COMPARATOR): Patients at high risk for venous thromboembolism (criteria: age\>=40, pelvic fracture, lower extremity fracture, shock on presentation, spinal cord injury, head injury with AIS \>=3) who also have a contraindication to anticoagulant(enoxaparin)administration such as renal failure with creatine clearance \<30 mL/min, head injury with head AIS \>=3), uncontrolled hemorrhage, uncorrected coagulopathy, persistent thrombocytopenia. These patients will receive mechanical compression.
- 2A (Type: EXPERIMENTAL): Patients at very high risk for venous thromboembolism (criteria: major operative procedure, venous injury, ventilator days \>3, 2 or more high risk factors). These patients will receive fondaparinux 2.5mg SubQ daily and mechanical compression.
- 2B (Type: ACTIVE_COMPARATOR): Patients at very high risk for venous thromboembolism (criteria: major operative procedure, venous injury, ventilator days \>3, 2 or more high risk factors) who also have a contraindication to anticoagulant(enoxaparin)administration such as renal failure creatine clearance \<30 mL/min, head injury with head AIS \>=3), uncontrolled hemorrhage, uncorrected coagulopathy, persistent thrombocytopenia. These patients will receive mechanical compression and possibly temporary inferior vena cava (IVC) filter(as determined by the patient's care givers).

Based on this trial design, predict the completion outcome and termination type (if applicable).